APPLICATION OF AN INNOVATIVE DESIGN SPACE OPTIMIZATION STRATEGY TO THE DEVELOPMENT OF LC METHODS TO COMBAT POTENTIALLY COUNTERFEIT NONSTEROIDAL ANTIINFLAMMATORY DRUGS
NSAIDs; Substandard and Counterfeit drugs; Design of experiments; Design space; Method transfer; Accuracy profile
Abstract :
[en] In the context of the battle against counterfeit medicines, an innovative methodology has been used to develop rapid and specific high performance liquid chromatographic methods to detect and determine 18 non-steroidal anti-inflammatory drugs, 5 pharmaceutical conservatives, paracetamol, chlorzoxazone, caffeine and salicylic acid. These molecules are commonly encountered alone or in combination on the market. Regrettably, a significant proportion of these consumed medicines are counterfeit or substandard, with a strong negative impact in countries of Central Africa. In this context, an innovative design space optimization strategy was successfully applied to the development of LC screening methods allowing the detection of substandard or counterfeit medicines. Using the results of a unique experimental design, the design spaces of 5 potentially relevant HPLC methods have been developed, and transferred to an ultra high performance liquid chromatographic system to evaluate the robustness of the predicted DS while providing rapid methods of analysis. Moreover, one of the methods has been fully validated using the accuracy profile as decision tool, and was then used for the quantitative determination of three active ingredients and one impurity in a common and widely used pharmaceutical formulation. The method was applied to 5 pharmaceuticals sold in the Democratic Republic of Congo. None of these pharmaceuticals was found compliant to the European Medicines Agency specifications
APPLICATION OF AN INNOVATIVE DESIGN SPACE OPTIMIZATION STRATEGY TO THE DEVELOPMENT OF LC METHODS TO COMBAT POTENTIALLY COUNTERFEIT NONSTEROIDAL ANTIINFLAMMATORY DRUGS
Publication date :
12 September 2012
Journal title :
Journal of Chromatography. A
ISSN :
0021-9673
eISSN :
1873-3778
Publisher :
Elsevier Science, Amsterdam, Netherlands
Volume :
1263
Pages :
113-124
Peer reviewed :
Peer Reviewed verified by ORBi
Name of the research project :
-
Funders :
Commission universitaire pour le Développement - CUD; Walloon Region of Belgium; Belgium National Fund for Scientific Research (FRS-FNRS)
Commentary :
The manuscript highlights a combination of two aspects, analytical method development leading to analytical tools and counterfeit of medicines that corrupts the world and in particular low-income countries that have very low or even no means to combats this scourge.
Polášek, M., Pospíšilová, M., Urbánek, M., (2000) J. Pharm. Biomed. Anal., 23, p. 135
Iuliani, P., Carlucci, G., Marrone, A., (2010) J. Pharm. Biomed. Anal., 51, p. 46
Lebrun, P., Govaerts, B., Debrus, B., Ceccato, A., Caliaro, G., Hubert, P., (2008) Chemom. Intell. Lab. Syst., 91, p. 4
(2011), http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf, The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Q8(R2) Pharmaceutical Development, (accessed June)
Marini, R.D., Hubert, P., Rozet, E., Vander Heyden, Y., Ziemons, E., Boulanger, B., Bouklouze, A., Crommen, J., (2007) J. Pharm. Biomed. Anal., 44, p. 640
Schweitzer, M., Pohl, M., Hanna-Brown, M., Nethercote, P., Borman, P., Hansen, G., Smith, K., Larew, J., (2010) Pharm. Technol., 34, p. 52
Ermer, J., (2011) Eur. Pharm. Rev., 16, p. 16
Nethercote, P., Borman, P., Bennett, T., Martin, G., Mcgregor, P., (2010) Pharm. Manuf., p. 37. , April
Borman, P., Roberts, J., Jones, C., Hanna-Brown, M., Szucs, R., Bale, S., (2010) Sep. Sci., 2, p. 1
Debrus, B., Lebrun, P., Mbinze Kindenge, J., Lecomte, F., Ceccato, A., Caliaro, G., Mavar Tayey Mbay, J., Hubert, P., (2011) J. Chromatogr. A, 1218, p. 5205
Peterson, J.J., (2008) J. Biopharm. Stat., 18, p. 959
Sacré, P.-Y., Deconinck, E., Chiap, P., Crommen, J., Mansion, F., Rozet, E., Courselle, P., De Beer, J.O., (2011) J. Chromatogr. A, 1218, p. 6439
Hubert, P., Nguyen-Huu, J.J., Boulanger, B., Chapuzet, E., Chiap, P., Cohen, N., Compagnon, P.A., Valat, L., (2004) J. Pharm. Biomed. Anal., 36, p. 579
Bouabidi, A., Rozet, E., Fillet, M., Ziemons, E., Chapuzet, E., Mertens, B., Klinkenberg, R., Hubert, P., (2010) J. Chromatogr. A, 1217, p. 3180
Council of Europe (2011), European Pharmacopoeia, ed. 7.2, Strasbourg, France,, monographs 1061900-1061901
(2012), http://www.r-project.org/, R Development Core Team, The R Project for Statistical Computing
Guillarme, D., Nguyen, D., Rudaz, S., Veuthey, J.-L., (2007) Eur. J. Pharm. Biopharm., 66, p. 475
Guillarme, D., Nguyen, D., Rudaz, S., Veuthey, J.-L., (2008) Eur. J. Pharm. Biopharm., 68, p. 430
Debrus, B., Lebrun, P., Ceccato, A., Caliaro, G., Govaerts, B., Olsen, B., Rozet, E., Hubert, P., (2009) Talanta, 79, p. 77
Gupta, A., Nagar, D., (1999) Matrix Variate Distributions, , Chapman and Hall/CRC, Boca Raton, FL
Dewé, W., Govaerts, B., Boulanger, B., Rozet, E., Chiap, P., Hubert, P., (2007) Chemom. Intell. Lab. Syst., 85, p. 262
Rozet, E., Marini, R.D., Ziemons, E., Boulanger, B., Hubert, P., (2011) J. Pharm. Biomed. Anal., 55, p. 848
The European Medicines Agency (1996), http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002916.pdf, Note for Guidance on Manufacture of The Finished Dosage Form, CPMP/QWP/486/95, April, (accessed June 2011)
The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human (2011), http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf, Use, Q2(R1) Analytical Validation, (accessed June)
Boulanger, B., Rozet, E., Moonen, F., Rudaz, S., Hubert, P., (2009) J. Chromatogr. B, 877, p. 2235
Rozet, E., Marini, R.D., Ziemons, E., Hubert, P., Dewé, W., Rudaz, S., Boulanger, B., (2011) Trends Anal. Chem., 30, p. 797